As previously reported, Craig-Hallum initiated coverage of Veracyte (VCYT) with a Buy rating and $45 price target The firm sees a lot of upside to estimates, which should drive the stock. Further, Craig-Hallum sees Veracyte as a “sleep at night” story, with market-leading products with room for growth, industry-leading margins, a strong balance sheet, positive cash flows, and a management team with a history of consistent beats and raises.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- Veracyte initiated with a Buy at Craig-Hallum
- Veracyte’s Strong Market Position and Growth Potential Drive Buy Rating
- Veracyte Inc. Reports Strong 2024 Earnings Amid Challenges
- Veracyte’s Strong Q4 2024 Performance and Strategic Moves Justify Buy Rating
- Veracyte Inc. Reports Strong 2024 Financial Performance